This page separates reported trial results from statistical interpretation. The numerical results on this page are restricted to the ClinicalTrials.gov data posted on ClinicalTrials.gov for PALOMA-3. The registry provides three posted primary-endpoint analyses, all concerning pharmacokinetic exposure or concentration measures.
1. Trial at a Glance
PALOMA-3 is a randomized, parallel, open-label phase 3 study in participants with EGFR-mutated advanced or metastatic non-small cell lung cancer. The study compares lazertinib with amivantamab administered as a subcutaneous co-formulation with recombinant human hyaluronidase against lazertinib with intravenous amivantamab, with the registered primary analyses focused on amivantamab pharmacokinetic concentration and exposure measures.
| Feature | PALOMA-3 |
|---|---|
| Trial name | PALOMA-3 |
| ClinicalTrials.gov identifier | NCT05388669 |
| Phase | Phase 3 |
| Therapeutic area | Oncology |
| Condition | Advanced or Metastatic Non-small Cell Lung Cancer |
| Population descriptor | Participants with epidermal growth factor receptor (EGFR)-mutated advanced or metastatic non-small cell lung cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 418.0 |
| Arms | 2 |
| Lead sponsor | Janssen Research & Development, LLC |
| Sponsor type | Industry |
| Status | Active, not recruiting |
2. Clinical Question
The central statistical question is whether administering amivantamab subcutaneously as a co-formulation with recombinant human hyaluronidase produces amivantamab pharmacokinetic exposure and concentration measures that are non-inferior to those observed with intravenous amivantamab when both treatment strategies include lazertinib.
Population
Participants with EGFR-mutated advanced or metastatic non-small cell lung cancer.
Intervention
Lazertinib with amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF).
Comparator
Lazertinib with amivantamab administered by intravenous (IV) infusion.
Primary question
Are the amivantamab pharmacokinetic concentration and exposure measures with SC-CF sufficiently preserved relative to IV administration under the registered non-inferiority framework?
This distinction is important. The registered primary endpoints are not overall survival, progression-free survival, tumor response, or another clinical outcome. They are pharmacokinetic measures of amivantamab concentration and exposure. Consequently, the principal statistical interpretation concerns comparability of drug exposure, not a direct estimate of comparative cancer-treatment efficacy.
3. Trial Design
Lazertinib + Amivantamab SC-CF
- Lazertinib
- Amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC CF)
Lazertinib + Amivantamab IV
- Lazertinib
- Amivantamab intravenous (IV infusion)
4. Primary Endpoints
ClinicalTrials.gov lists three primary endpoints. All three are pharmacokinetic measures, but they differ in whether they measure a steady-state trough concentration, an earlier trough concentration, or exposure over a specified interval.
| Primary endpoint | Time frame | Definition |
|---|---|---|
| For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State | Pre-dose on Cycle 4 Day 1 (each cycle of 28 days) | Ctrough was the observed serum concentration of Amivantamab at steady state immediately prior to the next drug administration. |
| For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab | Pre-dose on Cycle 2 Day 1 (each cycle of 28 days) | Ctrough was the observed serum concentration of Amivantamab immediately prior to the next drug administration. |
| Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2 | Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1 | AUC (Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15 were reported. |
Why these endpoints are different
A trough concentration and an area-under-the-curve measure summarize different aspects of pharmacokinetics. A Ctrough is a concentration observed immediately before the next administration. It is therefore a point measurement at a prespecified dosing time. An AUC, by contrast, summarizes exposure across an interval by integrating concentration over time.
That distinction matters statistically because an AUC ratio near 1.0 addresses overall exposure over the specified interval, whereas a Ctrough ratio addresses the concentration immediately before the next administration. The three primary analyses therefore provide related but non-identical evidence about pharmacokinetic comparability.
5. Statistical Methodology
The registry identifies non-inferiority as the hypothesis type for all three primary analyses. The stated primary hypothesis tests were based on a one-sided test at significance level alpha = 0.05 to demonstrate non-inferiority of amivantamab SC-CF relative to amivantamab IV.
| Feature | Registry information |
|---|---|
| Hypothesis type | Non-inferiority |
| Primary comparison | Arm A: Lazertinib With Amivantamab SC-CF vs Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion |
| Analysis direction as reported | Arm B Vs Arm A |
| Primary testing framework | One-sided test at alpha = 0.05 |
| Confidence intervals | 90%, two-sided |
| Formal method field | Not reported |
| Effect measure listed for first two analyses | Cox regression model |
| Effect measure for AUC analysis | Geometric mean ratio |
PK primary endpoint evaluable sets
The analysis populations are defined by pharmacokinetic evaluability rather than simply by enrollment. For the steady-state Cycle 4 Day 1 Ctrough analysis, the registry describes a PK primary endpoint evaluable set consisting of randomized participants who had received all doses in Cycles 1-3, without dose modifications, and provided a Cycle 4 Day 1 Ctrough. For the EU and applicable-region Cycle 2 Day 1 Ctrough analysis, the set included randomized participants who had received all doses in Cycle 1, without dose modifications, and provided the Cycle 2 Day 1 Ctrough.
For the Cycle 2 AUC analysis, the registry describes a PK primary endpoint evaluable set consisting of randomized participants who had received all doses up to Cycle 2 Day 1, without dose modifications, and provided all necessary PK samples to derive the primary endpoint.
6. Results: Primary Pharmacokinetic Endpoints
ClinicalTrials.gov contains three formal statistical analyses corresponding to the three registered primary endpoints. Each provides an effect estimate and a two-sided 90% confidence interval. The ClinicalTrials.gov record does not provide p-values, so none are added to the results.
6.1 Steady-State Ctrough — Cycle 4 Day 1
Reported primary estimate
Two-sided 90% CI: 1.266–1.610
Comparison reported as Arm B Vs Arm A
| Feature | Reported result |
|---|---|
| Endpoint | For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State |
| Time frame | Pre-dose on Cycle 4 Day 1 (each cycle of 28 days) |
| Unit | Micrograms per milliliters (mcg/mL) |
| Estimate | 1.427 |
| Confidence interval | 90% two-sided CI 1.266–1.610 |
| Hypothesis | Non-inferiority |
| Analysis direction | Arm B Vs Arm A |
The reported estimate of 1.427 is an arm-comparison estimate for the observed amivantamab Ctrough at steady state, with the registry specifying the comparison direction as Arm B versus Arm A. Numerically, an estimate above 1 means the reported quantity for Arm B is estimated to be higher relative to Arm A under the analysis as posted.
It does not mean that Arm B produces 42.7% greater clinical efficacy, nor does it mean that participants have a 42.7% greater probability of a clinical outcome. The endpoint is a pharmacokinetic concentration, not a clinical event endpoint.
The two-sided 90% confidence interval, 1.266–1.610, describes statistical uncertainty around the reported estimate under the analysis framework. It does not describe the range of Ctrough values for individual participants and does not by itself establish whether a prespecified non-inferiority margin has been met.
The registry states that non-inferiority was tested using a one-sided alpha of 0.05, but the ClinicalTrials.gov record does not state the numerical non-inferiority margin. Therefore, the confidence interval cannot be compared with a specific margin on this page. A non-inferiority conclusion requires the prespecified margin and the direction in which it is applied.
6.2 Ctrough — Cycle 2 Day 1
Reported primary estimate
Two-sided 90% CI: 1.040–1.261
Comparison reported as Arm B Vs Arm A
| Feature | Reported result |
|---|---|
| Endpoint | For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab |
| Time frame | Pre-dose on Cycle 2 Day 1 (each cycle of 28 days) |
| Unit | mcg/mL |
| Estimate | 1.145 |
| Confidence interval | 90% two-sided CI 1.040–1.261 |
| Hypothesis | Non-inferiority |
| Analysis direction | Arm B Vs Arm A |
The reported estimate of 1.145 compares the observed amivantamab Ctrough between the two randomized administration strategies in the direction specified by the registry. The point estimate is above 1, so the reported Arm B quantity is estimated to be higher than the corresponding Arm A quantity under the posted analysis.
That numerical difference should not be translated directly into a difference in tumor response, survival, or patient benefit. Ctrough is a pharmacokinetic concentration measured at a specified time point.
The 90% confidence interval of 1.040–1.261 gives a measure of precision around the estimated comparison. It indicates that the estimate is not being presented as an exact population quantity. As with the other primary analyses, the interval is not an interval for individual participant concentrations.
The p-value is not included in the ClinicalTrials.gov record. More importantly for a non-inferiority analysis, a p-value alone would not determine the non-inferiority conclusion. The prespecified margin, the direction of the comparison, and the corresponding confidence-interval criterion are central to the decision rule.
6.3 AUC Day 1–15 — Cycle 2
Geometric mean ratio
Two-sided 90% CI: 0.976–1.090
Effect measure: Ratio of geometric means
| Feature | Reported result |
|---|---|
| Endpoint | Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2 |
| Time frame | Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1 |
| Unit | Micrograms*hour per milliliters |
| Effect measure | Geometric mean ratio |
| Estimate | 1.032 |
| Confidence interval | 90% two-sided CI 0.976–1.090 |
| Hypothesis | Non-inferiority |
| Analysis direction | Arm B Vs Arm A |
The geometric mean ratio of 1.032 indicates that the geometric mean AUC in Arm B relative to Arm A was estimated at 1.032 under the reported comparison direction. On a ratio scale, 1.0 represents equal geometric means; 1.032 is therefore close to 1.0.
It does not mean that 3.2% more patients benefited from one administration strategy, nor does it describe a 3.2% change in a clinical outcome. It describes a ratio of pharmacokinetic exposure measures.
The two-sided 90% confidence interval of 0.976–1.090 provides the uncertainty around the geometric mean ratio. The interval crosses 1.0, which is the equality value for a ratio, but that fact alone does not answer the non-inferiority question. Non-inferiority is assessed against a prespecified margin rather than against the null value of equality alone.
The ClinicalTrials.gov record identifies the hypothesis as non-inferiority and specify a one-sided alpha of 0.05, but they do not provide the numerical margin. Consequently, this page can describe the estimate and its precision without assigning a formal non-inferiority conclusion based on an unstated margin.
7. How to Read the Three Primary Results Together
The three estimates should not be collapsed into one overall statistic. They address different pharmacokinetic summaries and different regional or cycle-specific conditions.
| Primary measure | Estimate | 90% two-sided CI | Statistical meaning |
|---|---|---|---|
| Steady-state Ctrough, Cycle 4 Day 1 | 1.427 | 1.266–1.610 | Relative comparison of observed steady-state trough concentration in the reported direction |
| Ctrough, Cycle 2 Day 1 | 1.145 | 1.040–1.261 | Relative comparison of observed trough concentration in the reported direction |
| AUC Day 1–15, Cycle 2 | 1.032 | 0.976–1.090 | Ratio of geometric mean exposure in the reported direction |
The AUC estimate is particularly straightforward to interpret on a ratio scale because its effect measure is explicitly identified as a geometric mean ratio. An estimate of 1.032 is close to the equality value of 1.0. The Ctrough analyses are different: although the registry reports “Cox regression model” in the effect-measure field, the endpoints themselves are continuous concentration measures and the record does not name a statistical method. That discrepancy should be preserved rather than silently converting the results into conventional hazard ratios.
For a ratio measure, 1.0 represents equality. Values above 1 indicate a higher quantity in the numerator arm, while values below 1 indicate a lower quantity. The clinical interpretation depends on what the underlying quantity measures and on the prespecified non-inferiority margin.
8. Non-Inferiority Logic
Non-inferiority trials ask a different question from superiority trials. The objective is generally not to show that the new strategy is better than the comparator. Instead, the design specifies an amount of loss that would be considered acceptable for the new strategy, and the observed data are evaluated against that prespecified margin.
Equality is not the margin
A ratio of 1.0 represents equality, but a non-inferiority design can permit a specified amount of deviation from equality.
The margin matters
The numerical margin determines what range of results is compatible with the prespecified non-inferiority claim.
Confidence intervals matter
Non-inferiority is commonly assessed using a confidence bound relative to the prespecified margin, rather than by asking only whether a p-value is below 0.05.
Direction matters
The registry identifies the comparison as Arm B Vs Arm A while stating the non-inferiority hypothesis for SC-CF relative to IV. The direction of the reported estimate therefore has to be read carefully.
Why the 90% confidence intervals are notable
The primary analyses report two-sided 90% confidence intervals. A two-sided 90% interval corresponds to a 5% probability allocated to each tail under the usual confidence-interval construction. The registry separately describes the hypothesis test as one-sided with alpha = 0.05. In a non-inferiority framework, this pairing is commonly connected through the equivalence between a one-sided 5% test and a two-sided 90% confidence interval, provided the interval and test are constructed from the same statistical model and estimator.
That connection does not remove the need to know the non-inferiority margin. The confidence interval supplies the uncertainty around the estimate; the margin supplies the prespecified boundary against which that uncertainty is evaluated.
9. Statistical Methods Explained
Why use a geometric mean ratio for AUC?
Pharmacokinetic exposure measures such as AUC can be analyzed on a multiplicative scale. A geometric mean ratio compares the typical exposure level between two groups in a way that is naturally suited to ratio-based interpretation. An estimate of 1.032 therefore means the estimated geometric mean exposure in the numerator arm is 1.032 times that of the denominator arm, under the comparison direction specified by the registry.
The ratio is not the same as an arithmetic mean difference. A difference of 10 units and a ratio of 1.10 answer different statistical questions and have different interpretations.
Why is 1.0 important for a ratio?
For a ratio, 1.0 is the equality value. If two geometric means were exactly equal, their ratio would be 1.0. A ratio of 1.032 is therefore close to equality on the multiplicative scale. But a ratio being close to 1.0 is not, by itself, the formal definition of non-inferiority.
Why is non-inferiority judged against a margin rather than simply a p-value?
A superiority p-value typically addresses a null hypothesis such as equality. Non-inferiority instead asks whether the new strategy is sufficiently close to the comparator according to a prespecified clinically or scientifically justified margin. A result can fail to demonstrate superiority while still satisfying a non-inferiority criterion, depending on the margin and the confidence interval.
For PALOMA-3, the ClinicalTrials.gov record explicitly identify a non-inferiority hypothesis and a one-sided alpha of 0.05, but the numerical margin is not reported. That means the posted estimates can be interpreted descriptively without reconstructing an unstated decision threshold.
What does the 90% confidence interval tell us?
The confidence interval quantifies uncertainty around the estimated treatment-group comparison under the specified statistical framework. For example, the AUC ratio is 1.032 with a two-sided 90% confidence interval of 0.976–1.090. The interval is narrower than it would be for a two-sided 95% confidence interval under the same estimator and standard-error structure, although the actual width depends on the analysis.
The interval does not tell us that 90% of individual participants will have ratios inside that range. It is a statement about uncertainty in the estimated population-level comparison under repeated-sampling reasoning.
Why does the analysis population differ from total enrollment?
The pharmacokinetic primary endpoint evaluable sets require specific dosing histories and the necessary concentration samples. A participant can therefore be randomized into the trial without contributing to every primary PK analysis. This is different from an efficacy analysis that might be defined simply by randomized assignment.
Why should the “Cox regression model” field be interpreted cautiously?
The ClinicalTrials.gov record lists “Cox regression model” as the reported effect measure for the two Ctrough analyses, while no statistical method is named. Cox regression is conventionally associated with time-to-event outcomes and hazard-based effects. Ctrough, however, is a continuous pharmacokinetic concentration. Because the ClinicalTrials.gov record does not provide enough detail to reconstruct the exact model specification, the appropriate educational approach is to report the field exactly as posted without relabeling the estimate as a conventional hazard ratio.
Why can a confidence interval cross 1.0 and still be compatible with non-inferiority?
Because equality and non-inferiority are different hypotheses. For the AUC analysis, the interval is 0.976–1.090 and therefore includes 1.0. That means exact equality cannot be ruled out in the usual two-sided sense represented by that interval. But non-inferiority does not require demonstrating superiority or even necessarily ruling out equality. What matters is whether the confidence bound satisfies the prespecified non-inferiority margin. The margin registry-reported to investigators is therefore essential to the formal interpretation.
10. Understanding the Analysis Direction
The statistical-analyses data state “Arm B Vs Arm A”. Arm A is lazertinib with amivantamab SC-CF, while Arm B is lazertinib with amivantamab IV infusion. The interpretation of a ratio therefore depends on keeping the numerator and denominator straight.
| Arm | Intervention | Role in reported comparison |
|---|---|---|
| Arm A | Lazertinib With Amivantamab SC-CF | Reference side of the reported Arm B Vs Arm A comparison |
| Arm B | Lazertinib With Amivantamab Intravenous (IV) Infusion | Comparison side of the reported Arm B Vs Arm A comparison |
This matters especially for non-inferiority. Saying that an estimate is “above 1” is incomplete unless the reader knows which arm is in the numerator. The registry's explicit comparison direction prevents the estimate from being casually interpreted in the opposite direction.
A ratio is not self-interpreting. Always identify what quantity is being compared, which arm is the numerator, which arm is the denominator, and what boundary defines non-inferiority. Omitting any of these can reverse the practical interpretation of a numerical result.
11. Safety Results
The ClinicalTrials.gov record reports serious adverse events by randomized arm. These are presented as affected participants over participants at risk.
| Safety measure | Arm A Lazertinib + Amivantamab SC-CF | Arm B Lazertinib + Amivantamab IV |
|---|---|---|
| Serious adverse events | 59/206 | 64/210 |
The ClinicalTrials.gov record is limited to serious adverse events by arm. It should therefore not be expanded into conclusions about overall adverse-event incidence, grade-specific toxicity, treatment discontinuation, or individual adverse-event categories.
The denominators also illustrate an important distinction from the overall trial enrollment of 418. The serious-adverse-event summary uses 206 participants in Arm A and 210 in Arm B as the affected/at-risk denominators reported in the ClinicalTrials.gov record. Those denominators sum to 416, not 418, so the safety table should not be silently presented as if it were a complete accounting of all 418 enrolled participants.
12. What the Primary Estimates Do — and Do Not — Mean
The reported 1.427 estimate describes the comparison of observed steady-state amivantamab Ctrough in the reported Arm B-versus-Arm-A direction. It does not mean a 42.7% improvement in cancer outcomes, a 42.7% higher probability of response, or a 42.7% difference in survival.
The reported 1.145 estimate describes the Cycle 2 Day 1 Ctrough comparison in the reported direction. It is a pharmacokinetic comparison at a specified pre-dose time point, not a measure of relative treatment efficacy.
The 1.032 geometric mean ratio indicates that the reported Arm B-to-Arm-A exposure ratio is close to 1.0. The 90% confidence interval of 0.976–1.090 expresses uncertainty around that estimate. Formal non-inferiority interpretation still requires the prespecified margin.
A p-value is a measure associated with a hypothesis-testing procedure; it is not a measure of the magnitude of pharmacokinetic similarity or difference. The ClinicalTrials.gov record does not report p-values for these three analyses. Even if they did, the p-value would not replace the effect estimate, confidence interval, and non-inferiority margin when interpreting a non-inferiority PK study.
13. Limitations
- Non-inferiority margin not reported: the registry data identify the non-inferiority hypothesis and one-sided alpha = 0.05 but do not provide the numerical margin, preventing a complete reconstruction of the formal decision boundary.
- Method specification is incomplete: no statistical method is named. The first two analyses identify “Cox regression model” as the effect measure, but the ClinicalTrials.gov record does not provide enough detail to reconstruct that model.
- PK evaluable populations: the primary analyses use pharmacokinetic evaluable sets requiring specified dosing histories and PK measurements rather than simply the full enrolled population.
- Different endpoint timing: the three primary endpoints use different cycles and time points. Ctrough at Cycle 4 Day 1 should not be treated as interchangeable with Ctrough at Cycle 2 Day 1 or with Cycle 2 AUC.
- Regional endpoint definitions: the first two primary endpoints apply to different regional groupings, with the first explicitly covering regions other than the EU and others accepting Cycle 2 Day 1 and the second covering the EU and any applicable region.
- Safety denominator distinction: the serious-adverse-event summary posted on ClinicalTrials.gov for the two arms uses 206 and 210 participants at risk, whereas overall enrollment is 418.
- No clinical efficacy results reported: the posted primary analyses in the ClinicalTrials.gov record concern PK endpoints. The ClinicalTrials.gov record does not support adding response, progression-free survival, overall survival, or other clinical efficacy results.
- No p-values reported: the statistical analyses provide estimates and 90% confidence intervals, but the ClinicalTrials.gov record does not contain p-values.
- Open-label design: masking is listed as none. This is relevant to subjective assessments and treatment-experience measures, although the primary endpoints described here are pharmacokinetic measurements.
14. Why This Trial Matters Statistically
PALOMA-3 is a useful statistical teaching case because the central problem is not a conventional superiority comparison of a clinical outcome. Instead, the trial illustrates how randomization, pharmacokinetic endpoints, ratio-scale estimation, confidence intervals, and non-inferiority testing fit together.
| Concept | How it appears in PALOMA-3 |
|---|---|
| Randomization | Participants are allocated randomly to two parallel treatment strategies. |
| Two-arm comparison | Lazertinib with amivantamab SC-CF is compared with lazertinib with amivantamab IV infusion. |
| Pharmacokinetic endpoint | Primary endpoints include observed amivantamab Ctrough and AUC. |
| Ratio-scale analysis | The AUC endpoint uses a geometric mean ratio. |
| Confidence intervals | All three posted primary analyses provide two-sided 90% confidence intervals. |
| Non-inferiority | The registered hypothesis is non-inferiority with a one-sided alpha of 0.05. |
| Analysis population | PK primary endpoint evaluable sets require specified dosing and PK data. |
| Analysis direction | The posted analyses specify Arm B Vs Arm A. |
| Method reporting | The statistical method is not reported; the first two analyses list “Cox regression model” as the reported effect measure. |
| Safety analysis | Serious adverse events are reported by arm as affected participants over participants at risk. |
15. Non-Inferiority Versus Superiority: A Statistical Distinction
It is tempting to read every randomized comparison as a search for a treatment effect greater than zero or a ratio different from 1.0. That framework is not sufficient for a non-inferiority trial.
Superiority question
Is the new strategy statistically distinguishable from the comparator in the favorable direction?
Non-inferiority question
Is the new strategy sufficiently close to the comparator according to a prespecified acceptable margin?
For PALOMA-3, the registry explicitly identifies the hypothesis as non-inferiority. This changes how the confidence intervals should be read. The AUC interval of 0.976–1.090 includes 1.0, but that alone neither proves nor disproves non-inferiority. The relevant question is whether the confidence bound lies within the prespecified acceptable range.
This is one reason why reporting only a p-value can be particularly misleading in non-inferiority work. A statistically significant result against equality can coexist with an estimate that is unfavorable in magnitude, while a nonsignificant superiority test can coexist with a valid non-inferiority conclusion. The estimand, margin, confidence interval, and analysis population must be considered together.
16. Pharmacokinetic Endpoint Interpretation
Ctrough
Ctrough is the observed serum concentration immediately before the next drug administration. In PALOMA-3, the first primary endpoint specifies steady-state Ctrough before dosing on Cycle 4 Day 1, while the second specifies Ctrough before dosing on Cycle 2 Day 1 for the EU and applicable regions.
These are point measurements. They do not summarize the entire concentration-time profile. A participant's Ctrough can therefore provide information about residual concentration immediately before another administration without providing the same information as total exposure over an interval.
AUC
AUC summarizes concentration over time. The registered PALOMA-3 AUC endpoint covers Cycle 2 Day 1 to Day 15, with the registry specifying different sampling descriptions for the two arms.
The area under the concentration-time curve integrates concentration across a specified time interval. The resulting quantity reflects cumulative exposure over that interval rather than concentration at a single instant.
For the AUC endpoint, the posted effect measure is a geometric mean ratio. This makes the analysis naturally interpretable on a multiplicative scale. The estimate of 1.032 can therefore be read as a ratio close to unity, while the 90% confidence interval provides the corresponding uncertainty range.
17. Analysis Populations and the Meaning of “Evaluable”
The ClinicalTrials.gov record distinguishes the PK primary endpoint evaluable sets according to the amount of dosing and PK information available.
| Endpoint | PK evaluable-set requirement described in the registry |
|---|---|
| Cycle 4 Day 1 Ctrough | Randomized participants who received all doses in Cycle 1-3, without dose modifications, and provided Cycle 4 Day 1 Ctrough. |
| Cycle 2 Day 1 Ctrough | Randomized participants who received all doses in Cycle 1, without dose modifications, and provided Cycle 2 Day 1 Ctrough. |
| Cycle 2 AUC | Randomized participants who received all doses up to Cycle 2 Day 1, without dose modifications, and provided all necessary PK samples to derive the primary endpoint. |
The progressively different requirements illustrate why an analysis estimate is always conditional on an analysis population. The Cycle 4 Ctrough analysis requires more treatment exposure and later sampling than the Cycle 2 analyses. Therefore, the three estimates should not automatically be interpreted as if they were calculated from identical sets of participants.
18. Safety and Efficacy Should Remain Separate
The registry-reported PALOMA-3 data contain both PK primary results and serious-adverse-event counts. These should be presented as separate evidence streams rather than combined into an informal benefit-risk score.
Pharmacokinetics
Answers questions about observed concentration and drug exposure under the specified dosing and sampling framework.
Safety
Describes serious adverse events among the participants included in the registry-reported at-risk denominators.
Non-inferiority
Provides a formal framework for assessing whether a specified new strategy remains within an acceptable margin.
Clinical outcomes
Would address outcomes such as response or survival, but such results are not part of the ClinicalTrials.gov record for this page.
This separation is particularly important because a PK non-inferiority result does not automatically establish clinical non-inferiority for every possible clinical endpoint. Pharmacokinetic comparability and clinical outcome comparability are related questions but are not mathematically identical estimands.
19. Record Summary
PALOMA-3 is a randomized phase 3, parallel, open-label trial with 418.0 enrolled participants and two treatment arms. The registered primary endpoints are pharmacokinetic: two observed amivantamab Ctrough measures and one Cycle 2 AUC measure. The registry identifies non-inferiority as the hypothesis type and states that the primary hypothesis tests used a one-sided alpha of 0.05.
The three posted primary estimates are 1.427 for steady-state Ctrough with a two-sided 90% confidence interval of 1.266–1.610, 1.145 for Cycle 2 Day 1 Ctrough with a two-sided 90% confidence interval of 1.040–1.261, and a 1.032 geometric mean ratio for Cycle 2 AUC with a two-sided 90% confidence interval of 0.976–1.090. The analysis direction is reported as Arm B Vs Arm A.
The central statistical lesson is that these numbers must be interpreted in the context of pharmacokinetic estimands, ratio-scale effects, endpoint-specific evaluable populations, confidence intervals, and non-inferiority margins. The ClinicalTrials.gov record does not provide the numerical non-inferiority margin or p-values, so this page does not manufacture either one. The first two analyses also contain a reporting inconsistency in which “Cox regression model” appears as the reported effect measure while no statistical method is named; that should be acknowledged rather than converted into an assumed conventional hazard-ratio analysis.
20. Related Tutorials
Learn more about the methods used in this trial:
21. Related Calculators
22. Sources
- ClinicalTrials.gov: NCT05388669 — PALOMA-3.
- Linked publication: PubMed record: PMID 42635093.
- Linked publication: PubMed record: PMID 38857463.
Continue through Clinical Biostats
Explore statistical tutorials, calculators, and additional clinical-trial analyses covering the methods used to design, analyze, and interpret randomized studies.